Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

AmBisome Now Approved In UK For Presumed Fungal Infections BOULDER, CO -- Aug. 18, 1998 -- The Medicines Control Agency of the United Kingdom has approved a new indication for NeXstar Pharmaceuticals, Inc.’s AmBisome, a liposomal formulation of amphotericin B, to include empirical treatment for presumed fungal infections in febrile neutropenic patients whose fever is resistant to broad-spectrum antibiotics and where a bacterial or viral cause has not been defined. The new label in the UK recommends that AmBisome therapy should be administered at doses of 3 mg/kg/day and that treatment should be continued until the recorded temperature is normalised for three consecutive days, with a maximum duration of treatment of 42 days. AmBisome now has first line indications in 17 countries world-wide, including the United States. Patients at risk for systemic (blood-borne) fungal infections include those with compromised immune systems, such as patients receiving stem cell or bone marrow transplants, patients undergoing cancer treatment and HIV-infected individuals. Patients afflicted with systemic fungal infections have low levels of infection-fighting white blood cells and exhibit persistent fever that does not resolve despite large-spectrum antibiotic treatment. These fungal infections are often lethal in the absence of effective therapy. Related Links: AmBisome, NeXstar Pharmaceuticals, Inc. E-mail this page to a friend or colleague! To print, use this version